KOSDAQBiotech & Pharma205470

Humasis

₩2,180▲ 0.69%2026-11-18 close
Market Cap
₩53.8B
Turnover
₩87,890,394
Volume
40K
Shares out.
24.7M
PER
—
PBR
0.3×
EPS
-₩793
Dividend Yield
0.00%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩0 per share · Prices as of the 2026-11-18 close

01

Report overview

Full treasury share cancellation; narrowing losses is the next test

Humasis disclosed the full cancellation of its treasury shares on November 13, 2026, but it has reported losses in each year from 2023 to 2025 and operating losses for five straight quarters through the third quarter of 2026, so whether profits recover is the key variable.

  1. 1

    On November 13, 2026, Humasis disclosed the full cancellation of 2,056,081 treasury shares, about 8.3% of issued shares, with cancellation scheduled for November 23. It had also cancelled treasury shares worth KRW 21.1 billion in the first half of 2026.

  2. 2

    Sales in 2025 rose 18.5% to KRW 30.1 billion, but the company still posted an operating loss of KRW 10.6 billion and a net loss attributable to controlling shareholders of KRW 15.6 billion.

  3. 3

    Third-quarter 2026 sales fell 34.6% year on year to KRW 5.66 billion, and the operating loss of KRW 3.47 billion extends a loss run that began in the third quarter of 2025.

  4. 4

    The company swung to a profit attributable to controlling shareholders of KRW 3.47 billion in the first quarter of 2026, but returned to losses in the second and third quarters.

  5. 5

    Over the last four quarters the net loss attributable to controlling shareholders totals KRW 18 billion, so no price-to-earnings ratio is calculated.

02

Business structure

Humasis was founded in 2000 and listed on KOSDAQ in 2017.

It is an in-vitro diagnostics company that has focused on research, development and production of POCT (point-of-care testing) immunoassay reagents, along with automated immunoassay equipment, multiplex test reagents and rapid kits, according to a technical analysis report from March 2022.

Its consolidated sales mix, however, has moved well away from that core. Based on FnGuide data for December 2025, entertainment accounted for 50.37% of sales, medical device manufacturing and sales for 33.68%, and the POCT business for 15.95%. Entertainment therefore makes up close to half of revenue.

That segment runs through a consolidated subsidiary that plans and produces drama, film and music content for domestic and overseas OTT platforms, and the same subsidiary manufactures condoms and medical rubber products.

The group built this structure by acquiring a stake in that subsidiary in May 2024, and in November 2024 it bought a 9.67% stake in Kyungnam Pharm.

At its 2024 annual shareholder meeting, the company approved mineral development and sales as a new business purpose, and a mineral production subsidiary was established in March 2024. In in-vitro diagnostics, its business overlaps with companies such as Osang Healthcare.

No segment-level sales or operating profit figures were confirmed in disclosures, so only the sales mix is shown. With the POCT share at 15.95%, how the new businesses are reflected in reported results is the central question for understanding the company's structure.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩8.7B-₩2.5B−28.3%
2025Q4₩6.4B-₩3.3B−51.8%
2026Q1₩8.9B-₩1.6B−18.2%
2026Q2₩7.7B-₩3.3B−42.8%
2026Q3₩5.7B-₩3.5B−61.3%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩471.3B₩214.7B₩182.6B45.6%52.7%34.8%
2023₩13.8B-₩52.4B-₩55.4B−378.6%−19.3%20.9%
2024₩25.4B-₩10.6B-₩30.4B−41.5%−13.3%33.2%
2025₩30.1B-₩10.6B-₩15.6B−35.0%−7.3%38.9%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-13

04

Earnings analysis

On a reported basis, sales fell 97.1% from KRW 471.3 billion in 2022 to KRW 13.8 billion in 2023. That drop followed the surge in COVID-19 test kit exports, when 2021 consolidated sales reached KRW 321.8 billion, up 604.0% year on year, according to a March 2022 technical analysis report.

Sales then rose 83.8% to KRW 25.4 billion in 2024 and 18.5% to KRW 30.1 billion in 2025, two consecutive years of increases after the 2023 low, though the level remains far below 2022.

The operating margin fell from 45.6% in 2022 to -378.6% in 2023, when the operating loss of KRW 52.4 billion suggests that fixed costs weighed more heavily than the sales decline alone.

The margin improved to -41.5% in 2024 and -35.0% in 2025, but the company has recorded losses for three consecutive years from 2023 to 2025.

The net loss attributable to controlling shareholders narrowed from KRW 55.4 billion in 2023 to KRW 30.4 billion in 2024 and KRW 15.6 billion in 2025, while the net loss including non-controlling interests was KRW 55.4 billion, KRW 35.6 billion and KRW 21.7 billion over the same years.

The two figures differ because non-controlling interests are included in the latter. Operating cash flow swung from negative KRW 55.5 billion in 2023 to positive KRW 25 billion in 2024 and KRW 10.1 billion in 2025.

Quarterly results show a sharp volatility: the third quarter of 2025 posted sales of KRW 8.65 billion, an operating loss of KRW 2.45 billion and a profit attributable to controlling shareholders of KRW 679 million, but the fourth quarter swung to a net loss of KRW 8.53 billion on sales of KRW 6.42 billion.

Sales peaked at KRW 8.92 billion in the first quarter of 2026, when the company returned to a profit of KRW 3.47 billion attributable to controlling shareholders.

Sales then declined to KRW 7.74 billion in the second quarter, with a net loss of KRW 11.2 billion, and to KRW 5.66 billion in the third quarter, with an operating loss of KRW 3.47 billion and a net loss of KRW 1.7 billion.

Over the last four quarters the net loss attributable to controlling shareholders totals KRW 18 billion, and whether the first-quarter profit repeats is the next checkpoint for the company's quarterly earnings.

05

Industry analysis

Demand for in-vitro diagnostics tends to follow infectious disease cycles, and Humasis's results show that pattern clearly. Its 2021 consolidated sales of KRW 321.8 billion reflected the surge in COVID-19 test kit exports, according to a March 2022 technical analysis report.

The fall to KRW 13.8 billion in 2023 can be read as normalizing demand for that product group flowing straight into earnings. The company then built a structure that grew entertainment and medical device manufacturing alongside its POCT immunoassay business rather than placing POCT back at the center.

POCT accounted for only 15.95% of sales in the FnGuide data for December 2025. In in-vitro diagnostics, it competes with companies such as Osang Healthcare, but no disclosure-based data on growth or market share relative to those peers was available, so no numerical comparison is made.

Other listed companies in the biopharma sector focus mainly on new drugs or biologics, which means their business models and profit structures differ from Humasis.

Price competition in domestic diagnostics, overseas export approvals and the frequency of infectious disease outbreaks are variables that reported results alone cannot size.

Read this way, Humasis is an in-vitro diagnostics company whose sales have swung with infectious disease demand, and it now operates as a mixed business in which entertainment and medical devices carry much of the weight.

06

Outlook

The company has stated that it will improve profitability through business stabilization and new businesses, and use the resulting funds to continue its shareholder return policy, according to reports of the November 13, 2026 disclosure.

The treasury share cancellation was reported at KRW 36.1 billion, with cancellation scheduled for November 23. Combined with the KRW 21.1 billion cancelled in the first half, it makes two large rounds of shareholder returns in 2026.

Coverage also noted that the effect of cancellation depends on timing and business results.

On the new business side, the mineral production subsidiary was established in March 2024, and the company's 2025 year-end commentary said the entertainment segment is widening its revenue base through increased production investment in domestic and overseas OTT platforms and a more diversified set of buyers.

In February 2025, the company closed several branches, including sites in Uiwang and Anyang, to adjust its cost structure. On governance, the representative director changed in March 2026, and as of September 11, 2026 INCON Co., Ltd. was listed among the top shareholders with a 10.06% stake.

The next checkpoints on results are whether the 2026 full-year operating margin improves from -35.0% in 2025 and whether the first-quarter 2026 profit level holds. The timing when the new businesses start contributing to earnings has not yet been confirmed in disclosures.

07

Valuation

PER
—
PBR
0.3×
ROE
-8.3%
EPS
-₩793
BPS
₩9,244
Dividend per share
₩0

Valuation reads best when net assets and earnings are considered side by side. The price-to-book ratio sits well below 1x, and market capitalization is low relative to the book value attributable to controlling shareholders.

At the end of 2025, total equity was KRW 235.4 billion, of which KRW 215.1 billion belonged to controlling shareholders.

Earnings-based multiples, by contrast, cannot be calculated: the net loss attributable to controlling shareholders over the last four quarters totals KRW 18 billion, so no price-to-earnings ratio is shown, and earnings-based comparisons only become possible after a return to profit.

The debt-to-equity ratio rose from 20.9% in 2023 to 38.9% in 2025, with total liabilities of KRW 91.7 billion at the end of 2025. Shareholder returns have leaned toward treasury share cancellation rather than cash dividends, at KRW 21.1 billion in the first half of 2026 and KRW 36.1 billion scheduled for November.

Cancellation reduces the number of shares and can lift per-share measures, but while the company remains loss-making, earnings-based valuation improvement is limited. A market value far below book value alongside losses is the starting point for reading this company's valuation.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-13

08

Bull factors

Concrete shareholder return steps

The full cancellation of treasury shares disclosed on November 13, 2026 equals about 8.3% of issued shares, with cancellation scheduled for November 23. It follows KRW 21.1 billion of cancellations in the first half, so a second round is proceeding this year.

The company said the decision reflected demands for higher corporate value raised at a shareholder meeting. Cancelling shares reduces the share count and can raise value per share.

A quarterly swing back to profit

In the first quarter of 2026, the company returned to a profit of KRW 3.47 billion attributable to controlling shareholders, and its operating loss narrowed to KRW 1.63 billion from KRW 3.32 billion in the fourth quarter of 2025.

The net loss attributable to controlling shareholders then shrank from KRW 11.2 billion in the second quarter to KRW 1.7 billion in the third quarter. Narrower loss quarters are consistent with the company's stated stabilization plan. However, the third-quarter operating loss of KRW 3.47 billion was larger than in the previous quarter.

Balance sheet and cash generation

Operating cash flow was positive KRW 10.1 billion in 2025, after swinging from negative KRW 55.5 billion in 2023 to positive KRW 25 billion in 2024 and remaining positive. At the end of 2025, total equity was KRW 235.4 billion and total liabilities KRW 91.7 billion, with a debt-to-equity ratio of 38.9%.

Equity is larger than liabilities, so the balance sheet is not under strain. Most of that equity, KRW 215.1 billion, is attributable to controlling shareholders, which supports the company's financial capacity.

09

Bear factors

Sales decline and falling quarters

Sales fell from KRW 471.3 billion in 2022 to KRW 30.1 billion in 2025, and after peaking at KRW 8.92 billion in the first quarter of 2026, they declined in both the second and third quarters. Third-quarter 2026 sales of KRW 5.66 billion were down 34.6% year on year.

The recovery in 2024 and 2025 remains small compared with the 2022 level. Continued declines from the first-quarter peak are the largest pressure on upcoming quarterly results.

Persistent operating losses

The company has recorded operating losses for five consecutive quarters from the third quarter of 2025 through the third quarter of 2026, and the third-quarter 2026 operating loss of KRW 3.47 billion widened from the prior quarter. The 2025 operating margin of -35.0% is far below the 45.6% of 2022.

With losses in each year from 2023 to 2025, a recovery in the profit structure has not yet appeared in reported results. The net loss attributable to controlling shareholders over the last four quarters totals KRW 18 billion, which means accumulated losses would need to be offset even after a return to profit.

Concentration in entertainment and uncertain new businesses

Based on FnGuide data for December 2025, entertainment made up 50.37% of sales and the POCT business 15.95%. With the core diagnostics business at a small share, earnings may depend heavily on entertainment sales and distribution.

The timing of any profit contribution from the mineral business or the Kyungnam Pharm stake has not been confirmed in disclosures. Press coverage also noted that the real effect of treasury share cancellation depends on timing and business results.

10

Risk factors

Earnings volatility and business structure

Consolidated sales reached KRW 321.8 billion in 2021 before falling to KRW 13.8 billion in 2023, and sales were KRW 30.1 billion in 2025. The earlier pattern, in which sales fell sharply once infectious disease demand receded, is already on record.

Quarterly sales have also declined since the first-quarter 2026 peak, so short-term volatility is high. New businesses in entertainment and minerals have not yet shown up clearly in profits, which remains a risk.

Financial capacity and shareholder return funding

The debt-to-equity ratio rose from 20.9% in 2023 to 38.9% in 2025, and operating cash flow fell from KRW 25 billion in 2024 to KRW 10.1 billion in 2025.

Treasury share cancellations reached KRW 21.1 billion in the first half of 2026 and KRW 36.1 billion is scheduled, and the company has said it needs additional funds to keep up its return policy. If operating cash flow and capital capacity fall short, the funding for these returns could be constrained.

Management and ownership changes

The representative director changed in March 2026, and the major shareholder structure also shifted during the year. As of September 11, 2026, INCON Co., Ltd. was listed as a major shareholder with 10.06%.

Running business stabilization and new-business strategy at the same time as management and ownership change carries execution risk. If the strategic direction shifts during this period, the timing of any earnings recovery could also slip.

11

What to watch next

  1. November 23, 2026

    Scheduled date for cancelling all treasury shares. Completion will be confirmed through disclosure of the change in issued shares, and it will show whether the stated shareholder return policy is being carried out.

  2. December 31, 2026 (fiscal year end)

    The end of fiscal 2026. The checkpoints are whether the first-quarter 2026 profit recurs in later quarters and whether the full-year operating loss narrows from 2025.

  3. End of March 2027

    Deadline for the 2026 annual report. Fourth-quarter and full-year 2026 results will first appear in the periodic report, and the key points are whether 2026 sales exceed the 2025 level of KRW 30.1 billion and whether the net loss attributable to controlling shareholders falls below KRW 15.6 billion.

  4. Around May 15, 2027

    Deadline for the first-quarter 2027 report. The checkpoints are whether quarterly sales recover from the KRW 5.66 billion of the third quarter of 2026 and whether the operating loss narrows.

12

Overall view

Humasis grew sales on the back of the COVID-19 test kit export boom, reaching KRW 321.8 billion in 2021, but sales fell to KRW 13.8 billion in 2023 and stood at KRW 30.1 billion in 2025.

The company has recorded losses in each year from 2023 to 2025, and operating losses have run for five straight quarters through the third quarter of 2026, so a profit recovery is not yet visible in reported results.

On the other hand, it returned to a profit attributable to controlling shareholders in the first quarter of 2026, and operating cash flow stayed positive in 2024 and 2025.

Full treasury share cancellation and the push into new businesses clearly point toward shareholder returns and diversification, but when these will show up in earnings has not been confirmed in disclosures. The sales mix, with entertainment at 50.37%, also changes the character of the earnings.

The next checkpoints are the completion of the cancellation on November 23, 2026, the 2026 annual report due by the end of March 2027, and the first-quarter 2027 report.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 17 more articles and sources
  1. thevc.kr
  2. sentv.co.kr
  3. etoday.co.kr
  4. comp.wisereport.co.kr
  5. m.sedaily.com
  6. comp.fnguide.com
  7. m.news.nate.com
  8. ssl.pstatic.net
  9. saramin.co.kr
  10. investing.com
  11. comp.wisereport.co.kr
  12. idigitalnomad.net
  13. sankun.com
  14. comp.wisereport.co.kr
  15. jobkorea.co.kr
  16. investing.com
  17. judal.co.kr

Report written 2026-11-14 · Data as of 2026-11-13

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis